Threatened circumferential margin in mid-rectal cancer: choosing neoadjuvant treatment
A 60-year-old man is diagnosed with adenocarcinoma of the mid-rectum, 7 cm from the anal verge, after presenting with rectal bleeding and a change in bowel habit. Pelvic MRI shows cT3c disease with 4 mm extramural extension, extramural venous invasion, and a threatened circumferential resection margin of 1 mm at the 4 o'clock position; three mesorectal nodes are suspicious. CT of the chest, abdomen and pelvis and a PET-CT show no distant metastases. CEA is 14 µg/L. He is fit, ECOG 0, with no comorbidity, and works full-time. He is keen to avoid a permanent stoma and asks whether he could avoid surgery altogether if the tumour disappears. The multidisciplinary team is divided between total neoadjuvant therapy, long-course chemoradiotherapy followed by TME, and short-course radiotherapy followed by TME.
1. Which neoadjuvant strategy do you recommend, and what does the threatened margin mean for his question about avoiding surgery?
Read the worked answer
The threatened circumferential resection margin dominates the decision. A 1 mm margin at the 4 o'clock position means tumour is at the mesorectal fascia; the priority is to achieve an R0 resection and reduce local recurrence, and secondarily to gain systemic control, because extramural venous invasion signals a high risk of micrometastatic disease.
Recommendation: total neoadjuvant therapy (TNT) - for example short-course radiotherapy (25 Gy in 5 fractions) followed by consolidation FOLFOX, or long-course chemoradiotherapy followed by consolidation chemotherapy. Trials such as RAPIDO and PRODIGE 23 showed improved disease-free survival and higher pathological complete response rates with TNT, with more R0 resections in high-risk MRI-defined disease.
Alternatives and why they are less attractive here:
- Long-course chemoradiotherapy (capecitabine with 50.4 Gy in 28 fractions) then TME is acceptable but gives a lower complete response rate and delays systemic treatment.
- Short-course radiotherapy alone then TME suits lower-risk disease but provides less downstaging and less systemic cover, which is a problem with a threatened margin and venous invasion.
On avoiding surgery: the threatened margin makes watch-and-wait unsafe as a default. He should be told that a complete response may occur and can be discussed in a structured programme, but that the baseline MRI predicts a high chance of microscopic residual disease, so surgery remains the recommendation. A temporary ileostomy is likely; a permanent stoma is not inevitable.
2. He achieves a clinical complete response after TNT. How would you counsel him about watch-and-wait, and what surveillance would it require?
Read the worked answer
Counsel honestly about the uncertainty. A clinical complete response is not the same as a pathological complete response; up to a quarter of patients with cCR harbour residual tumour. With a baseline threatened margin, the risk of microscopic residual disease is higher than average, so watch-and-wait should be offered only within a structured programme and with explicit documentation of the trade-offs.
Confirming cCR: digital rectal examination, flexible endoscopy and MRI including diffusion-weighted imaging, usually 8–12 weeks after completing treatment, with a biopsy of any residual abnormality. CEA should normalise.
Surveillance if he chooses watch-and-wait:
- DRE and CEA every 3 months for the first 2 years.
- MRI every 3–6 months for the first 2–3 years, then less frequently.
- Endoscopy at 3, 6 and 12 months, then annually.
- Local regrowth occurs in roughly 25–30% of patients, mostly within 2 years; most can still be salvaged with TME and achieve R0.
What he must understand: surveillance is intensive and he must be able to attend; regrowth may require abdominoperineal excision, which carries a higher risk of a permanent stoma than immediate TME. If he does not achieve cCR, proceed to TME 6–8 weeks after finishing neoadjuvant treatment.
3. During week 3 of pelvic chemoradiotherapy he develops grade 2 diarrhoea, perianal pain and a neutrophil count of 1.1 ×10⁹/L. How do you manage this, and what would make you interrupt treatment?
Read the worked answer
First exclude infection and assess hydration. Check stool culture and C. difficile if he has had antibiotics, review electrolytes and renal function, and assess for dehydration. A neutrophil count of 1.1 ×10⁹/L is grade 2 neutropenia and is not itself an emergency in an afebrile patient, but it lowers the threshold for stopping capecitabine.
Symptom control:
- Loperamide 4 mg initially then 2 mg after each loose stool, with a maximum of 16 mg/day; stop if the diarrhoea resolves.
- Avoid lactulose and other osmotic laxatives; maintain oral fluids with electrolyte replacement.
- Perianal skin care: barrier cream, sitz baths, and topical local anaesthetic; exclude a perianal abscess if pain is disproportionate.
- Simple analgesia (paracetamol) and review of the radiation field for excessive dose to the anal canal.
When to interrupt or modify:
- Hold capecitabine for grade 3 diarrhoea, febrile neutropenia, or grade 3–4 mucositis, and on recovery consider a dose reduction (for example to 75% of the planned dose).
- Interrupt radiotherapy for grade 3 diarrhoea or severe proctitis that prevents hydration; a short break is preferable to uncontrolled toxicity, but prolonged interruptions compromise local control, so aim to complete treatment within the planned overall time.
- If diarrhoea persists despite these measures, examine for a radiation-induced stricture or fistula, and involve the surgical team early.